The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma.
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Pfizer/EMD Serono; Sanofi; Tolmar Therapeutics
Speakers' Bureau - AstraZeneca; Bayer; Genentech/Roche; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Gurkamal S. Chatta
Consulting or Advisory Role - Cardinal Health
Research Funding - Abbvie (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - Cardinal Health
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - DAVA Oncology; FLASCO; Sanofi
 
Helen H. Moon
Honoraria - EMD Serono; Pfizer/EMD Serono
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst); Xenocor
Travel, Accommodations, Expenses - Aveo; Bayer; Seagen
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO; Exelixis
Consulting or Advisory Role - AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); Pyxis (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Scott Edward Delacroix
No Relationships to Disclose
 
Alana Fang
No Relationships to Disclose
 
Leonard A. D'amico
No Relationships to Disclose
 
Angela Shaulov Kask
No Relationships to Disclose
 
Steven P. Fling
Research Funding - Alkermes (Inst); Genentech (Inst); Merck (Inst); NeoImmuneTech (Inst)
 
Andreanne Lacroix
Research Funding - Genentech (Inst); NeoImmuneTech (Inst); Revimmune (Inst)
 
Judith C. Kaiser
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Evan Y. Yu
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Bayer; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)